stockrow
Friday 6 November 2026
Export CTMX’s income statement to Excel — free account
CytomX Therapeutics, Inc.
CTMX Healthcare Biotechnology
CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024.
- Revenue
- −71.7%
- EPS
- 0.00%
- Free cash flow
- +204.1%
Quarter to September 2026, against a year earlier
2.19
0.05
+2.34%
Follow CTMX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 2 | 2 |
+8 more TTM periods Free account |
| (45.08%) | (39.18%) | (36.03%) | (41.34%) | ||
| (33.82%) | (29.72%) | (27.15%) | (14.97%) | ||
ROIC |
(20.82%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(28.25%) | (24.72%) | (19.41%) | (20.66%) | |
Average Days of Receivables |
13.04 | 747.75 | 6.63 | 9.64 | |
Free Cash Flow per Share |
(0.23) | (0.38) | (0.45) | (0.55) | |
Free Cash Flow |
(50.90) | (82.41) | (80.09) | (75.81) | |
Capital Expenditures |
(0.69) | — | — | (0.22) | |
| Other line items | |||||
Cash ROIC |
(17.87%) | (13.01%) | (12.01%) | (32.11%) | |
Accounts Receivable Turnover |
13.17 | 0.93 | 27.32 | 29.79 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.01 | |
Research and Development Expense of Revenue |
531.48% | 400.91% | 194.41% | 90.19% | |
Selling, General and Administrative Expense of Revenue |
244.98% | 175.28% | 87.50% | 39.16% | |
Share Based Compensation of Revenue |
82.73% | 55.44% | 25.32% | 8.27% | |
Operating CF/Net income |
0.57 | 1.00 | 1.29 | 3.71 | |
Depreciation/Fixed assets |
0.00 | (2.38) | (1.13) | (0.64) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.27 | |
Revenue per Share |
0.06 | 0.08 | 0.20 | 0.55 | |
Operating CF per Share |
(0.23) | (0.38) | (0.45) | (0.55) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026